Animal models for benign prostatic hyperplasia

19Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Although the etiology of benign prostatic hyperplasia (BPH) is unknown, various animal models have been used for several decades to identify potential therapeutic approaches. These models can be divided into those measuring smooth muscle tone and those measuring cellular proliferation. Animal models have played an important role in the development of the two drug classes currently approved for the treatment of BPH: the α-adrenoceptor antagonists and the steroid 5-α-reductase inhibitors. However, models measuring prostatic tone have not been particularly useful in the identification of new α-adrenoceptor antagonists having advantages over currently available drugs, and it is not certain that reduction of prostatic smooth muscle tone is responsible for the relief of BPH symptoms. A further limitation with BPH models is that prostatic hyperplasia similar to the human condition does not occur spontaneously or cannot be induced in any suitable animal species. The identification of a more useful BPH model is focused on cellular mechanisms of prostatic growth, looking similarities between humans and experimental animals. © 2011 Springer-Verlag Berlin Heidelberg.

Cite

CITATION STYLE

APA

Hieble, J. P. (2011). Animal models for benign prostatic hyperplasia. Handbook of Experimental Pharmacology, 202, 69–79. https://doi.org/10.1007/978-3-642-16499-6_4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free